Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Total Non-Current Liabilities (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $47.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 1.09% to $47.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $47.4 million, a 1.09% decrease, with the full-year FY2024 number at $50.7 million, down 20.09% from a year prior.
  • Total Non-Current Liabilities was $47.4 million for Q3 2025 at Werewolf Therapeutics, down from $48.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $74.0 million in Q1 2023 to a low of $7.1 million in Q1 2021.
  • A 5-year average of $43.1 million and a median of $47.3 million in 2025 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 411.14% in 2022, then decreased 29.7% in 2024.
  • Werewolf Therapeutics' Total Non-Current Liabilities stood at $26.5 million in 2021, then skyrocketed by 42.53% to $37.7 million in 2022, then surged by 68.25% to $63.5 million in 2023, then decreased by 20.09% to $50.7 million in 2024, then dropped by 6.53% to $47.4 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Total Non-Current Liabilities are $47.4 million (Q3 2025), $48.5 million (Q2 2025), and $47.3 million (Q1 2025).